Immuneering Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Immuneering Corporation on June 11, 2026. The filing details the voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
At the meeting, 44,495,059 shares were present, representing approximately 68.8% of outstanding Class A common stock. All proposals were approved:
- Item 1 (Director Election): Peter Feinberg and Laurie B. Keating were elected as Class II directors to serve until the 2029 Annual Meeting.
- Item 2 (Auditor Ratification): The appointment of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Attendance at the Annual Meeting was 68.8% of outstanding shares.
- Both director nominees received zero votes against them.
- RSM US LLP was ratified as the auditor for the 2026 fiscal year.
- Broker non-votes totaled 16,066,699 for the director election but were zero for the auditor ratification.